Head-to-head evidence
amycretin vs SAL0150
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
amycretin
Developed by Novo Nordisk
NCT06542874 · Phase 2 · completed
This was a randomized, quadruple-blinded, placebo-controlled trial with 448 participants and a validated diabetes disease-control endpoint (HbA1c). The primary comparison was clearly positive, with HbA1c reductions of up to 1.8 percentage points (subcutaneous) and 1.5 points (oral) that were statistically significant against placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2028 · NCT07400107 (registry estimate)
SAL0150
Developed by Shenzhen Salubris Pharmaceuticals
NCT05782192 · Phase 3 · completed
The study was randomized, quadruple-masked, and included both active and placebo comparator groups, with 458 participants. Its primary endpoint was the surrogate measure of HbA1c change. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amycretin's landscape · SAL0150's landscape